---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-26-000023"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-07-31T11:51:32+00:00"
generated_at: "2026-07-31T11:55:07.911981+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q2 2026: adj. EPS $3.65 (+22.9% YoY), revenue $16.99B (+10.2%); announces $10.9B Apogee acquisition

## Summary
- GAAP diluted EPS $2.03 (+290.4% YoY); adjusted diluted EPS $3.65 (+22.9% YoY); includes $0.17 IPR&D impact.
- Net revenues $16.99B (+10.2% reported, +9.5% operational); Immunology $8.786B (+15.1%) led by Skyrizi $5.505B (+24.4%).
- Neuroscience $3.228B (+20.3%); Oncology $1.650B (-1.5%); Aesthetics $1.282B (+0.3%).
- Announces definitive agreement to acquire Apogee Therapeutics for ~$10.9B equity value; expected close Q3 2026.
- Updates 2026 adj. EPS guidance to $13.87-$14.07 (from $13.91-$14.11); includes $0.14 dilutive impact from Apogee.

## SEC filing metadata
- accession: 0001551152-26-000023
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-07-31T11:51:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/0001551152-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-26-000023
- JSON: https://secwatch.observer/filing/0001551152-26-000023.json
- Plain text: https://secwatch.observer/filing/0001551152-26-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.